Robert Chioini

Robert Chioni is a pro in terms of multi-channel distribution, new market identification, intellectual property, licensing, marketing and sales, clinical drug development, pharmaceuticals, medical devices, finance, IPO, manufacturing, distribution, commercialization, strategic positioning, and U.S. Congressional and Government Agency relations.

Robert Chioni manages Rockwell Medical which is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients.

Rockwell Medical’s initial focus is the treatment of anemia in end-stage renal disease (ESRD). Rockwell Medical’s exclusive renal drug therapy, Triferic® (ferric pyrophosphate citrate), is the only FDA-approved therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Rob Chioni is the founder of Rockwell Medical which is also an established manufacturer, supplier, and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

Robert Chioni is a pro in terms of multi-channel distribution, new market identification, intellectual property, licensing, marketing and sales, clinical drug development, pharmaceuticals, medical devices, finance, IPO, manufacturing, distribution, commercialization, strategic positioning, and U.S. Congressional and Government Agency relations.